Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

UPLC/ESI-MS/MS-based determination of metabolism of several new illicit drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5F-QUPIC and α-PVT, by human liver microsome.

Takayama T, Suzuki M, Todoroki K, Inoue K, Min JZ, Kikura-Hanajiri R, Goda Y, Toyo'oka T.

Biomed Chromatogr. 2014 Jun;28(6):831-8. doi: 10.1002/bmc.3155.

PMID:
24861751
3.

Schedules of Controlled Substances: Placement of PB-22, 5F-PB-22, AB-FUBINACA and ADB-PINACA into Schedule I. Final rule.

Drug Enforcement Administration, Department of Justice.

Fed Regist. 2016 Sep 6;81(172):61130-3.

4.

Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA.

Wohlfarth A, Castaneto MS, Zhu M, Pang S, Scheidweiler KB, Kronstrand R, Huestis MA.

AAPS J. 2015 May;17(3):660-77. doi: 10.1208/s12248-015-9721-0. Epub 2015 Feb 28.

5.

Enantioseparation of the carboxamide-type synthetic cannabinoids N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide and methyl [1-(5-fluoropentyl)-1H-indazole-3-carbonyl]-valinate in illicit herbal products.

Doi T, Asada A, Takeda A, Tagami T, Katagi M, Kamata H, Sawabe Y.

J Chromatogr A. 2016 Nov 18;1473:83-89. doi: 10.1016/j.chroma.2016.10.049. Epub 2016 Oct 19.

PMID:
27773389
6.

Schedules of controlled substances: temporary placement of four synthetic cannabinoids into Schedule I. Final order.

Drug Enforcement Administration, Department of Justice.

Fed Regist. 2014 Feb 10;79(27):7577-82.

7.

Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA.

Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Glass M, Connor M, McGregor IS, Kassiou M.

ACS Chem Neurosci. 2015 Sep 16;6(9):1546-59. doi: 10.1021/acschemneuro.5b00112. Epub 2015 Jul 17.

PMID:
26134475
11.

In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid.

Carlier J, Diao X, Wohlfarth A, Scheidweiler K, Huestis MA.

Curr Neuropharmacol. 2016 Nov 8. [Epub ahead of print]

PMID:
27829332
12.

The synthesis and characterization of the 'research chemical' N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide (3,5-AB-CHMFUPPYCA) and differentiation from its 5,3-regioisomer.

McLaughlin G, Morris N, Kavanagh PV, Power JD, Twamley B, O'Brien J, Talbot B, Dowling G, Brandt SD.

Drug Test Anal. 2016 Sep;8(9):920-9. doi: 10.1002/dta.1864. Epub 2015 Sep 11.

PMID:
26360802
13.

Identification and analytical characterization of six synthetic cannabinoids NNL-3, 5F-NPB-22-7N, 5F-AKB-48-7N, 5F-EDMB-PINACA, EMB-FUBINACA, and EG-018.

Liu C, Jia W, Hua Z, Qian Z.

Drug Test Anal. 2017 Aug;9(8):1251-1261. doi: 10.1002/dta.2160. Epub 2017 Feb 24.

PMID:
28063270
14.

In vitro and in vivo human metabolism of the synthetic cannabinoid AB-CHMINACA.

Erratico C, Negreira N, Norouzizadeh H, Covaci A, Neels H, Maudens K, van Nuijs AL.

Drug Test Anal. 2015 Oct;7(10):866-76. doi: 10.1002/dta.1796. Epub 2015 Apr 12.

PMID:
25865117
15.

Identification of AB-FUBINACA metabolites in authentic urine samples suitable as urinary markers of drug intake using liquid chromatography quadrupole tandem time of flight mass spectrometry.

Vikingsson S, Gréen H, Brinkhagen L, Mukhtar S, Josefsson M.

Drug Test Anal. 2016 Sep;8(9):950-6. doi: 10.1002/dta.1896. Epub 2015 Nov 11.

PMID:
26560240
16.

Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry.

Carlier J, Diao X, Scheidweiler KB, Huestis MA.

Clin Chem. 2017 May;63(5):1008-1021. doi: 10.1373/clinchem.2016.267575. Epub 2017 Mar 16.

PMID:
28302730
17.

The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities.

Longworth M, Banister SD, Mack JBC, Glass M, Connor M, Kassiou M.

Forensic Toxicol. 2016;34:286-303. doi: 10.1007/s11419-016-0316-y. Epub 2016 Apr 27.

18.

AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.

Wiley JL, Marusich JA, Lefever TW, Antonazzo KR, Wallgren MT, Cortes RA, Patel PR, Grabenauer M, Moore KN, Thomas BF.

J Pharmacol Exp Ther. 2015 Sep;354(3):328-39. doi: 10.1124/jpet.115.225326. Epub 2015 Jun 23.

19.

Synthetic cannabimimetic agents metabolized by carboxylesterases.

Thomsen R, Nielsen LM, Holm NB, Rasmussen HB, Linnet K; INDICES Consortium.

Drug Test Anal. 2015 Jul;7(7):565-76. doi: 10.1002/dta.1731. Epub 2014 Oct 24.

PMID:
25346527
20.

Metabolic profiling of new synthetic cannabinoids AMB and 5F-AMB by human hepatocyte and liver microsome incubations and high-resolution mass spectrometry.

Andersson M, Diao X, Wohlfarth A, Scheidweiler KB, Huestis MA.

Rapid Commun Mass Spectrom. 2016 Apr 30;30(8):1067-78. doi: 10.1002/rcm.7538.

PMID:
27003044

Supplemental Content

Support Center